Skip to main content

Market Overview

Turning Point's RET Inhibitor Candidate Shows Tolerable Safety Profile, Early Signals Of Activity In Solid Tumor Settings

Share:
Turning Point's RET Inhibitor Candidate Shows Tolerable Safety Profile, Early Signals Of Activity In Solid Tumor Settings
  • Turning Point Therapeutics Inc (NASDAQ: TPTX) has reported initial data from the ongoing Phase 1/2 SWORD-1 study evaluating its RET inhibitor drug candidate, TPX-0046, in adult subjects with advanced or metastatic solid tumors harboring RET mutations or alterations.
  • Data from the Phase 1 dose-finding portion of the study showed preliminary clinical activity, including objective responses and a generally well-tolerated safety profile.
  • TPX-0046 was generally well tolerated, with the most frequent treatment-emergent adverse event being mild to moderate dizziness.
  • The maximum tolerated dose had not been determined, with one dose-limiting toxicity of treatment-related moderate gait disturbance at 30 mg dose.
  • Of five RET TKI-naïve patients, four showed tumor regressions of -42%, -37%, -23%, and -3%, including two patients dosed at 30 mg who achieved confirmed partial responses with a duration of responses of 5.6 and 5.8+ months, respectively.
  • Of 9 TKI-pretreated patients, three patients achieved tumor regressions of -44%, -27%, and -17%.
  • The company also plans to revise the study protocol to include Phase 1 expansion cohorts in up to 75 patients with RET-altered malignancies.
  • Price Action: TPTX shares are trading 0.50% lower at $89.50 in the premarket session on the last check Tuesday.
 

Related Articles (TPTX)

View Comments and Join the Discussion!

Posted-In: Briefs cancer Solid TumorBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com